Literature DB >> 7819028

Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.

M Gigante1, G Toffoli, M Boiocchi.   

Abstract

The potential for the modification of the pharmacokinetics of doxorubicin (DOX) concurrently administered with high-dose verapamil (VER) has been investigated in 17 patients with advanced neoplasms refractory to drugs belonging to the multidrug resistance spectrum. Steady-state concentration of DOX, systemic clearance and urinary excretion were analysed. No significant difference was found between the kinetic parameters estimated for DOX at different levels of VER and those reported for doxorubicin as single agent. It can be concluded that VER does not appear to modify DOX kinetics.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7819028      PMCID： PMC2033454          DOI： 10.1038/bjc.1995.27

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance.

Authors:  M Boiocchi; G Toffoli
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.

Authors:  L Zanette; M Zucchetti; A Freshi; D Erranti; U Tirelli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.

Authors:  G M Lai; Y N Chen; L A Mickley; A T Fojo; S E Bates
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

5.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

6.  Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations.

Authors:  Z B Salama; C Dilger; W Czogalla; R Otto; H Jaeger
Journal:  Arzneimittelforschung       Date:  1989-02

7.  The effect of verapamil on the pharmacokinetics of adriamycin.

Authors:  D J Kerr; J Graham; J Cummings; J G Morrison; G G Thompson; M J Brodie; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

9.  Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil.

Authors:  G Toffoli; L Tumiotto; M Gigante; M G Dall'Arche; T Perin; M Boiocchi
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Authors:  B L Lum; S Kaubisch; A M Yahanda; K M Adler; L Jew; M N Ehsan; N A Brophy; J Halsey; M P Gosland; B I Sikic
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544
View more
  1 in total

Review 1.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.